Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
US Cardiology Review is Scopus-indexed (Q3, CiteScore 2), DOAJ. Published by Radcliffe Medical Media.
Checked against the index lists dated .
ISSN 1758-3896Verify ISSN ↗1758-390XVerify ISSN ↗
Publisher: Radcliffe Medical Media
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Cardiology and Cardiovascular Medicine | 263 / 409 | 35th | Q3 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2016–present (also 2011–2012), best quartile Q3, CiteScore 2.
US Cardiology Review is Q3 in Cardiology and Cardiovascular Medicine (rank 263 of 409), by CiteScore 2025.
US Cardiology Review is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 2, quartile Q3, 35th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.450, quartile Q3, with an H-index of 10.
The publisher lists an article processing charge of about US$2,146 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
US Cardiology Review is published by Radcliffe Medical Media. Its print ISSN is 1758-3896 and its online ISSN is 1758-390X.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
US Cardiology Review has an h-index of 15 and a 2-year mean of 2.91 citations per paper (OpenAlex). Its Scopus CiteScore is 2, quartile Q3. On 2-year citations it ranks #69 of 398 Scopus journals in Cardiology and Cardiovascular Medicine.
US Cardiology Review published 25 papers in 2025; its busiest recent year was 2021 with 27. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2022–2026), authors are most often from United States (82.6%), United Kingdom (2.8%) and Saudi Arabia (2.3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.